학술논문
Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept.
Document Type
Academic Journal
Author
Salehjahromi M; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.; Karpinets TV; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA.; Sujit SJ; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.; Qayati M; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.; Chen P; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.; Aminu M; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.; Saad MB; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.; Bandyopadhyay R; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.; Hong L; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA; Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Sheshadri A; Department of Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX USA.; Lin J; Department of Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX USA.; Antonoff MB; Department of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, TX, USA.; Sepesi B; Department of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, TX, USA.; Ostrin EJ; Department of General Internal Medicine, MD Anderson Cancer Center, Houston, TX, USA.; Toumazis I; Department of Health Services Research, MD Anderson Cancer Center, Houston, TX, USA.; Huang P; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.; Cheng C; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.; Cascone T; Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Vokes NI; Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Behrens C; Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Siewerdsen JH; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA; Institute for Data Science in Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Hazle JD; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.; Chang JY; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Zhang J; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA.; Lu Y; Department of Nuclear Medicine, MD Anderson Cancer Center, Houston, TX, USA.; Godoy MCB; Department of Thoracic Imaging, MD Anderson Cancer Center, Houston, TX, USA.; Chung C; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; Institute for Data Science in Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Jaffray D; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA; Institute for Data Science in Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Wistuba I; Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA.; Lee JJ; Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.; Vaporciyan AA; Department of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, TX, USA.; Gibbons DL; Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Gladish G; Department of Thoracic Imaging, MD Anderson Cancer Center, Houston, TX, USA.; Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.; Wu CC; Department of Thoracic Imaging, MD Anderson Cancer Center, Houston, TX, USA.; Zhang J; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA; Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; Lung Cancer Genomics Program, MD Anderson Cancer Center, Houston, TX, USA; Lung Cancer Interception Program, MD Anderson Cancer Center, Houston, TX, USA.; Wu J; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA; Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; Institute for Data Science in Oncology, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jwu11@mdanderson.org.
Source
Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Subject
Language
English
Abstract
[ 18 F]Fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are indispensable components in modern medicine. Although PET can provide additional diagnostic value, it is costly and not universally accessible, particularly in low-income countries. To bridge this gap, we have developed a conditional generative adversarial network pipeline that can produce FDG-PET from diagnostic CT scans based on multi-center multi-modal lung cancer datasets (n = 1,478). Synthetic PET images are validated across imaging, biological, and clinical aspects. Radiologists confirm comparable imaging quality and tumor contrast between synthetic and actual PET scans. Radiogenomics analysis further proves that the dysregulated cancer hallmark pathways of synthetic PET are consistent with actual PET. We also demonstrate the clinical values of synthetic PET in improving lung cancer diagnosis, staging, risk prediction, and prognosis. Taken together, this proof-of-concept study testifies to the feasibility of applying deep learning to obtain high-fidelity PET translated from CT.
Competing Interests: Declaration of interests T.C. reports speaker fees and honoraria from The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; having an advisory role or receiving consulting fees from AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech, and Arrowhead Pharmaceuticals; and institutional research funding from AstraZeneca, Bristol Myers Squibb, and EMD Serono. L.Y. has grant support from Lantheus Inc. D.L.G. has served on scientific advisory committees for Menarini Ricerche, 4D Pharma, Onconova, and Eli Lilly and has received research support from Takeda, Astellas, NGM Biopharmaceuticals, Boehringer Ingelheim, and AstraZeneca. N.I.V. receives consulting fees from Sanofi, Regeneron, Oncocyte, and Eli Lilly and research funding from Mirati, outside the submitted work. J.D.H. is on the Scientific Advisory Board of Imagion Biosystems. J.Y.C. reports research funding from BMS-MDACC and Siemens Healthcare, and consultation fees from Legion Healthcare Partners. L.Y. has grant support from Lantheus Inc. M.C.B.G. has received research funding from Siemens Healthcare. I.W. has received honoraria from Genentech/Roche, AstraZeneca, Merck, Guardant Health, Flame, Novartis, Sanofi, Daiichi Sankyo, Dava Oncology, Amgen, GlaxoSmithKline, HTG Molecular, Jansen, Merus, Imagene, G1 Therapeutics, Abbvie, Catalyst Therapeutics, Genzyme, Regeneron, Oncocyte, Medscape, Platform Health, Pfizer, Physicians’ Education Resource, HPM Education, and Aptitute Health; additionally, I.W. has received research support from Genentech, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis, and Akoya. D.L.G. has served on scientific advisory committees for Menarini Ricerche, 4D Pharma, Onconova, and Eli Lilly and has received research support from Takeda, Astellas, NGM Biopharmaceuticals, Boehringer Ingelheim, and AstraZeneca. J.V.H. reports being on scientific advisory boards for AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, and Janssen Global Services; receiving research support from AstraZeneca, Takeda, Boehringer Ingelheim, and Spectrum; and receiving licensing fees from Spectrum. C.C.W. reports research support from Medical Imaging and Data Resource Center from NIBIB/University of Chicago and royalties from Elsevier. J.Z. reports serving on the consulting/advisory board of Bristol-Myers Squibb, AstraZeneca, Novartis, Johnson & Johnson, GenePlus, Innovent, Varian, and Catalyst, and receiving research grants to institution from Merck, Novartis, and Johnson & Johnson. J.W. reports research funding from Siemens Healthcare.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Competing Interests: Declaration of interests T.C. reports speaker fees and honoraria from The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; having an advisory role or receiving consulting fees from AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech, and Arrowhead Pharmaceuticals; and institutional research funding from AstraZeneca, Bristol Myers Squibb, and EMD Serono. L.Y. has grant support from Lantheus Inc. D.L.G. has served on scientific advisory committees for Menarini Ricerche, 4D Pharma, Onconova, and Eli Lilly and has received research support from Takeda, Astellas, NGM Biopharmaceuticals, Boehringer Ingelheim, and AstraZeneca. N.I.V. receives consulting fees from Sanofi, Regeneron, Oncocyte, and Eli Lilly and research funding from Mirati, outside the submitted work. J.D.H. is on the Scientific Advisory Board of Imagion Biosystems. J.Y.C. reports research funding from BMS-MDACC and Siemens Healthcare, and consultation fees from Legion Healthcare Partners. L.Y. has grant support from Lantheus Inc. M.C.B.G. has received research funding from Siemens Healthcare. I.W. has received honoraria from Genentech/Roche, AstraZeneca, Merck, Guardant Health, Flame, Novartis, Sanofi, Daiichi Sankyo, Dava Oncology, Amgen, GlaxoSmithKline, HTG Molecular, Jansen, Merus, Imagene, G1 Therapeutics, Abbvie, Catalyst Therapeutics, Genzyme, Regeneron, Oncocyte, Medscape, Platform Health, Pfizer, Physicians’ Education Resource, HPM Education, and Aptitute Health; additionally, I.W. has received research support from Genentech, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis, and Akoya. D.L.G. has served on scientific advisory committees for Menarini Ricerche, 4D Pharma, Onconova, and Eli Lilly and has received research support from Takeda, Astellas, NGM Biopharmaceuticals, Boehringer Ingelheim, and AstraZeneca. J.V.H. reports being on scientific advisory boards for AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, and Janssen Global Services; receiving research support from AstraZeneca, Takeda, Boehringer Ingelheim, and Spectrum; and receiving licensing fees from Spectrum. C.C.W. reports research support from Medical Imaging and Data Resource Center from NIBIB/University of Chicago and royalties from Elsevier. J.Z. reports serving on the consulting/advisory board of Bristol-Myers Squibb, AstraZeneca, Novartis, Johnson & Johnson, GenePlus, Innovent, Varian, and Catalyst, and receiving research grants to institution from Merck, Novartis, and Johnson & Johnson. J.W. reports research funding from Siemens Healthcare.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)